Dr. Hassan on the Rationale for Examining Talazoparib Plus Carboplatin in TNBC

April 14, 2021
Saima Hassan MD, PhD, FRCSC

Saima Hassan, MD, PhD, FRCSC, discusses the rationale for examining talazoparib in combination with carboplatin in patients with triple-negative breast cancer.

Saima Hassan, MD, PhD, FRCSC, a principal scientist and surgical oncologist at Centre de Recherche du CHUM, and an assistant professor in the Department of Surgery, Faculty of Medicine at Université de Montréal, discusses the rationale for examining talazoparib (Talzenna) in combination with carboplatin in patients with triple-negative breast cancer.

Talazoparib is a PARP inhibitor that has demonstrated potency in the preclinical setting due to its PARP DNA-trapping capacity, Hassan explains. The agent is clinically comparable to other PARP inhibitors like olaparib (Lynparza), which also has a high PARP DNA-trapping capacity, Hassan says.

In the metastatic setting, talazoparib has demonstrated efficiency in improving progression-free survival in patients with a BRCA mutation, as demonstrated in the phase 3 EMBRACA study (NCT01945775). The study demonstrated similar results to that of the phase 3 OlympiAD study (NCT02000622), which showed improved efficacy in patients with BRCA1/2-mutated metastatic breast cancer, Hassan concludes.